Methylin

Methylin is a brand-name formulation of methylphenidate hydrochloride, a central nervous system stimulant used in the treatment of attention-deficit/hyperactivity disorder (ADHD). The product is marketed in several oral forms, including an immediate-release liquid solution and chewable tablets; in some regions, extended-release versions are sold under similar names. Methylphenidate increases extracellular dopamine and norepinephrine in the brain by blocking their reuptake, which is believed to improve attention, impulse control, and hyperactivity in people with ADHD.

Methylin is approved for the management of ADHD in children and adults as part of a comprehensive treatment plan that may include behavioral therapy. In some jurisdictions, it may be prescribed for narcolepsy or other conditions, depending on local approval. The primary indication remains ADHD, with variations in formulation and labeling by country.

Methylin is a Schedule II controlled substance in the United States, reflecting a risk of dependence and abuse. It should not be used in individuals with known hypersensitivity to methylphenidate or to other stimulants; with severe anxiety, agitation, or Tourette syndrome; in patients with certain cardiovascular conditions; or with concomitant monoamine oxidase inhibitor therapy. Caution is advised in individuals with hypertension, glaucoma, bipolar disorder, or a history of substance use. Common adverse effects include decreased appetite, weight loss, insomnia, abdominal pain, headache, dizziness, and increased heart rate or blood pressure.

The medication is taken orally and comes in several strengths and formulations. Dosing is individualized and may be titrated to balance efficacy and tolerability while monitoring for adverse effects, growth in children, and cardiovascular status. See also: Methylphenidate, Ritalin.